EssilorLuxottica to Release New Research Findings at ARVO, Including Five-year Clinical Findings of Essilor Stellest Lenses
EssilorLuxottica to Release New Research Findings at ARVO, Including Five-year Clinical Findings of Essilor Stellest Lenses
Charenton-le-Pont, France (April 22, 2024) – EssilorLuxottica is proud to take part in the 2024 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, USA, where it will present new findings from its studies on advancements in myopia management with Essilor Stellest lenses, and on light management, focusing on topics such as light exposure and photochromic lenses. The full agenda can be viewed in the ARVO pocket guide here.
法國查倫頓勒邦（2024年4月22日）——EssilorLuxottica榮幸地參加在美國西雅圖舉行的視覺與眼科學研究協會（ARVO）2024年年會，屆時它將介紹其關於依視勒Steller鏡片近視管理進展以及光線管理研究的新發現，重點關注光曝光和光致變色鏡片等主題。完整的議程可以在 ARVO 袖珍指南中查看 這裏。
EssilorLuxottica R&D experts will once again be present to showcase their work among their peers. In addition to joining poster presentations and sponsored sessions, attendees will have the opportunity to stop by booth #4815 where they can meet the Group's experts, see what is new at research and development and discover how EssilorLuxottica is shaping the future of vision care through transformative technologies.
EssilorLuxottica研發專家將再次出席，向同行展示他們的作品。除了參加海報展示和贊助會議外，與會者還將有機會在 #4815 號展位停留，在那裏他們可以與集團的專家會面，了解研發領域的新進展，並了解EssilorLuxottica如何通過變革性技術塑造視力保健的未來。
The Company will also present the results of a five-year clinical follow-up study of its Essilor Stellest lenses for the first time. The findings strengthen the existing evidence base of the lenses in slowing down myopia progression in children. The data showed that the lenses save one- and three-quarter dioptres of myopia over five years,*1 demonstrating conclusive evidence of their efficacy in slowing down myopia progression in children in the fifth year.
該公司還將首次公佈其Essilor Stellest鏡頭爲期五年的臨床隨訪研究結果。這些發現加強了鏡片在減緩兒童近視進展方面的現有證據基礎。數據顯示，這些鏡片在五年內可挽救四分之一和四分之三的近視屈光度，*1 這證明了它們在第五年減緩兒童近視進展的確鑿證據。
The five-year results will be presented at an EssilorLuxottica sponsored session titled 'Novel approaches and models in myopia management: spectacle lenses with highly aspherical lenslets', on May 5 at 11:00 local time. Dr. Björn Drobe from EssilorLuxottica's R&D team will present the results, along with Prof. Mark Bullimore, MCOptom, PhD, FAAO who will present his insights on predictive models for axial elongation and change in myopia progression.
五年業績將在EssilorLuxottica贊助的題爲 “” 的會議上公佈近視管理的新方法和模型：帶有高度非球面鏡片的眼鏡片'，當地時間 5 月 5 日 11:00。來自EssilorLuxottica研發團隊的Bjorrn Drobe博士將介紹研究結果，FAAO的mcOpTom博士Mark Bullimore教授將介紹他對軸向伸長和近視進展變化的預測模型的見解。
On May 6 at 10:00 local time, Dr. Yee Ling Wong from EssilorLuxottica's R&D team and Prof. Mark Bullimore will discuss emmetropic eye growth and spectacle lenses with highly aspherical lenslets (HAL) based on findings from a recently published paper. This will be presented at a second sponsored myopia session titled 'Emmetropic eye growth as benchmark for myopia management using spectacle lenses with highly aspherical lenslets'. Essilor Stellest lenses are based on the optical design of HAL lenses. Both sessions will be moderated by Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica.
當地時間5月6日上午10點，來自essilorLuxottica研發團隊的黃怡玲博士和馬克·布利摩爾教授將根據最近發表的一篇論文的研究結果，討論等向性眼睛生長和帶有高度非球面鏡片（HAL）的眼鏡片。這將在第二屆贊助的近視會議上發表，題目是使用帶有高度非球面鏡片的眼鏡鏡片將Emmetropic眼睛生長作爲近視管理的基準'。Essilor Stellest 鏡頭基於 HAL 鏡頭的光學設計。這兩次會議都將由EssilorLuxottica醫療和專業事務主管奧爾加·普雷納特主持。
Norbert Gorny, Chief Scientific Officer at EssilorLuxottica, said, "We are excited to be able to share the latest five-year findings of HAL lenses at ARVO as long-term clinical data is essential to showcase the continued efficacy and performance of the lens in children. As we already know that every dioptre matters, we look forward to sharing scientific data and insights on interventions to address myopia, to bring us all one step closer to protecting the vision of young patients. We will also continue to integrate scientific knowledge with innovative technologies to create the future of myopia control spectacle lenses so that the next generation can see more and be more."
EssilorLuxottica首席科學官諾伯特·戈爾尼說，”我們很高興能夠在ARVO分享HAL鏡片的五年最新發現，因爲長期臨床數據對於展示該鏡片對兒童的持續療效和性能至關重要。我們已經知道每種屈光度都很重要，我們期待分享有關近視干預措施的科學數據和見解，從而使我們所有人離保護年輕患者的視力又近了一步。我們還將繼續將科學知識與創新技術相結合，創造近視控制眼鏡片的未來，讓下一代能夠看得更多，看得更多。“
"We are very happy to welcome attendees at our EssilorLuxottica booth where they can discover the company's innovative R&D capabilities and expertise in vision care and meet our R&D and Medical and Professional Affairs teams. The booth will also feature our Digital Infinite Refraction range consisting of Vision-R 800, Vision-S 700 and our specialized biometer, the Myopia Expert 700, designed to monitor myopia progression based on refraction and axial length for effective myopia management," said Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica.
“我們非常高興歡迎與會者光臨我們的EssilorLuxottica展位，他們可以在那裏了解公司的創新研發能力和視力保健方面的專業知識，並與我們的研發以及醫療和專業事務團隊會面。展位還將展出我們的數字無限折射系列，包括Vision-R 800、Vision-S 700和我們的專業生物計量儀近視專家700，旨在根據折射和軸向長度監測近視進展，以有效管理近視，” EssilorLuxottica醫療和專業事務主管奧爾加·普雷納特說。
Notes
*Compared to the 60-month progression of the Virtual Control Group (predicted average annual decrease in SER by 9.7%, Smotherman C, et al. IOVS 2023;64:ARVO E-Abstract 811).
1 Li X, Huang Y, Liu C, Yin Z, Cui Z, Lim EW, Drobe B, Chen H, Bao J. Myopia control efficacy of Spectacle Lenses with Highly Aspherical Lenslets: results of a 5-year follow-up study. ARVO Annual Meeting, Seattle. 2024. Available at: https://eppro02.ativ.me/web/page.php
注意事項
*與虛擬對照組60個月的進展相比（預計SER每年平均下降9.7％，Smotherman C等人。IOVS 2023; 64: ARVO 電子摘要 811)。
1 Li X、Huang Y、Liu C、Yin Z、Cui Z、Lim EW、Drobe B、Chen H、Bao J. 使用高度非球面鏡片的眼鏡鏡片的近視控制功效：一項爲期 5 年的隨訪研究結果。ARVO 年會，西雅圖。2024 年。可在以下網址獲得：https://eppro02.ativ.me/web/page.php